

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Leuven, BELGIUM – June 18, 2026 – 06:00 PM CET - [Oxurion NV](#) (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on June 17, 2026, from Atlas Special Opportunities II, LLC indicating that as of June 16, 2026, it held 10,958,882 shares of the then outstanding 111,049,581 shares, and therefore crossed under the threshold (10%) by virtue of the sales of voting securities.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is building a technology-enabled clinical research and software platform. The Company combines clinical operations expertise, software innovation and proprietary operational data to support pharmaceutical, biotechnology and medical device sponsors. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

<p>Oxurion NV Pascal Ghoson, Chief Executive Officer Pascal.ghoson@oxurion.com</p>

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

4) Notification by

A person that notifies alone

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities II LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

16/06/2026 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

10

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

111,049,581

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	14,310,803	10,958,882	0	9.87%	0.00%
TOTAL		10,958,882	0	9.87%	0.00%

Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction					
Holder of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
				0	0.00%	
TOTAL				0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	10,958,882	9.87%

CALCULATE

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

On 3 June 2026 (with settlement date on 5 June 2026), Atlas Special Opportunities II LLC sold 2,736,804 shares in Oxurion NV, as a result of which its shareholding decreased to 14,310,803 shares (= 12.887%, denominator = 111,049,581)
 On 4 June 2026 (with settlement date on 8 June 2026), Atlas Special Opportunities II LLC sold 1,224,300 shares in Oxurion NV, as a result of which its shareholding decreased to 13,086,503 shares (= 11.784%, denominator = 111,049,581)
 On 5 June 2026 (with settlement date on 9 June 2026), Atlas Special Opportunities II LLC sold 591,433 shares in Oxurion NV, as a result of which its shareholding decreased to 12,495,070 shares (= 11.252%, denominator = 111,049,581)
 On 8 June 2026 (with settlement date on 10 June 2026), Atlas Special Opportunities II LLC sold 247,040 shares in Oxurion NV, as a result of which its shareholding decreased to 12,248,030 shares (= 11.029%, denominator = 111,049,581)
 On 9 June 2026 (with settlement date on 11 June 2026), Atlas Special Opportunities II LLC sold 588,976 shares in Oxurion NV, as a result of which its shareholding decreased to 11,659,054 shares (= 10.499%, denominator = 111,049,581)
 On 10 June 2026 (with settlement date on 12 June 2026), Atlas Special Opportunities II LLC sold 246,717 shares in Oxurion NV, as a result of which its shareholding decreased to 11,412,337 shares (= 10.277%, denominator = 111,049,581)
 On 11 June 2026 (with settlement date on 15 June 2026), Atlas Special Opportunities II LLC sold 250,000 shares in Oxurion NV, as a result of which its shareholding decreased to 11,162,337 shares (= 10.052%, denominator = 111,049,581)
 On 12 June 2026 (with settlement date on 16 June 2026), Atlas Special Opportunities II LLC sold 203,455 shares in Oxurion NV, as a result of which its shareholding decreased to 10,958,882 shares (= 9.869%, denominator = 111,049,581)

Done at New York
 On 16/06/2026 (DD/MM/YYYY)
 Name & capacity Patrick Vance, Proxyholder

Signed by:
 Signature 
 9A8C4789B05442E...

